Abstract

MAGNESIUM GLYCINATE AND GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS: THERAPEUTIC IMPLICATIONS AND CLINICAL EVIDENCE

Thuribhatla Rohith*, Choddabattina Raj Kumar, Dr. Thripuramallu J. Mohan Rao

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, impaired insulin secretion, and persistent hyperglycemia. Magnesium is an essential mineral involved in glucose metabolism, insulin signaling, and cellular energy production, and inadequate magnesium status has been associated with impaired glycemic control and insulin resistance. Magnesium glycinate, an orally administered magnesium preparation, has gained interest as a potential adjunctive nutritional intervention in T2DM. Available clinical evidence on magnesium supplementation suggests modest improvements in fasting blood glucose, glycated hemoglobin (HbA1c), and insulin sensitivity in some patients. These effects may be related to the role of magnesium in insulin receptor signaling, glucose transport, enzymatic activity, and the regulation of oxidative stress and inflammation. However, most clinical studies have evaluatedmagnesium supplementation in general rather than magnesium glycinate specifically. Therefore, the direct evidence supporting magnesium glycinate for glycemic control remains limited. Magnesium glycinate may have potential as an adjunct to conventional diabetes management, but further well-designed clinical studies are required to establish its efficacy, optimal dosage, and long-term safety in patients with T2DM.

Keywords: Magnesium glycinate; Type 2 diabetes mellitus; Glycemic control; Insulin resistance; Insulin sensitivity; HbA1c; Blood glucose; Magnesium supplementation.